Stockreport

A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Relmada Therapeutics (RLMD) is back in focus after releasing 12 month interim Phase 2 data for NDV-01 in high risk non muscle invasive bladder cancer, alongside a rough [Read more]